Column: Key Takeaways from the SUSTAIN 340B Act and Things to Consider When Weighing In (Part 2)

Ted Slafsky, publisher and CEO of 340B Report, writes the second part of his two-part column on the Senate "group of six" 340B discussion draft.
In February, the U.S. Senate bipartisan “Group of Six” released an eagerly anticipated discussion draft bill and a bill summary/request [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Column: Key Takeaways from Senate Group of Six Draft 340B Bill (Part 1)

Ted Slafsky, publisher and CEO of 340B Report, writes the second part of his two-part column on the Senate "group of six" 340B discussion draft.
After reviewing comments from over 250 stakeholders, meeting with various interest groups and holding regular staff meetings, the U.S. Senate [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

COLUMN: Action on 340B Contract Pharmacies Turns to the States

Ted Slafsky, publisher and CEO of 340B Report, writes the second part of his two-part column on the Senate "group of six" 340B discussion draft.
As we approach the 16-month mark since we had pivotal arguments over the 340B contract pharmacy program in two federal [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Hospital Groups Urge Federal Court to Dismiss Drug Industry Suit Against Louisiana Law

Jeff Landry headshot
Four hospital associations filed an amicus brief in support of Louisiana Attorney General Jeff Landry's defense of his state's contract pharmacy law.
Four hospital associations are asking a federal judge in Louisiana to throw out a suit filed by the drug industry [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

A Tribute to Our Founding Editor in Chief from the Publisher and CEO

Ted Slafsky, publisher and CEO of 340B Report, calls retiring editor-in-chief Tom Mirga a "brilliant writer and reporter" in a tribute editorial.
When I thought about launching 340B Report, the first person I reached out to was Tom Mirga. Tom and I [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Column: Hospitals Are Not the Only 340B Providers Under Scrutiny

Ted Slafsky, publisher and CEO of 340B Report, writes the second part of his two-part column on the Senate "group of six" 340B discussion draft.
Veteran 340B observers were surprised to see that Sen. Bill Cassidy (R-La.) has expanded his 340B investigation into community health [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Column: Why the Genesis 340B Patient Definition Court Decision Could Resolve the Contract Pharmacy Impasse

Ted Slafsky, publisher and CEO of 340B Report, writes the second part of his two-part column on the Senate "group of six" 340B discussion draft.
In what legal experts describe as a landmark decision, the U.S. District Court for the District of South Carolina ruled [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Column: Look to The Senate for 340B Action

Ted Slafsky, publisher and CEO of 340B Report, writes the second part of his two-part column on the Senate "group of six" 340B discussion draft.
According to our history lessons, George Washington told Thomas Jefferson that the Senate was created to serve as a saucer [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Column: Could the States Resolve the Contract Pharmacy Impasse?

340B Report Publisher and CEO Ted Slafsky addresses enforcement actions and litigation surrounding state 340B contract pharmacy laws in his latest column.
After a recent lull in the ongoing battle over whether drug manufacturers can continue to place restrictions on access to [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B COVID-19 Flexibilities Will End May 11 as Public Health Emergency Expires

HRSA
340B program flexibilities allowed under the COVID-19 public health emergency will expire May 11, HRSA said Monday.

Certain flexibilities to the 340B program allowed under the COVID-19 public health emergency will expire May 11 alongside the PHE, the U.S. Health Resources and Services Administration announced Monday.

The update, which HRSA posted prominently on the Office of Pharmacy

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report